Clinical Trial Update: Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating apatinib as a third- or fourth-line treatment for advanced non-squamous non-small cell lung cancer with wild-type EGFR; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: UNKNOWN